Mirum Pharmaceuticals, Inc.
MIRMNASDAQHealthcare● Active
$92.02
$-1.47(-1.57%)
Market Cap$4.6B
P/E Ratio—
52W High$114.99
52W Low$43.5
Mirum Pharmaceuticals, Inc. (MIRM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MIRM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$13.43
Est. -$0.40 · -3257.5%
Revenue
$0.16B
Est. $0.15B · +7.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
MIRM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.46
Rev. $3.65B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.46
Rev. Est.$3.65B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$0.74 | — | — | — | $0.17B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$0.40 | -$13.43 | -3257.5% | $0.16B | $0.15B | +7.9% |
| ▼ Q1 FY2026 | Feb 25, 2026 | $0.02 | -$0.11 | -650.0% | $0.15B | $0.14B | +4.5% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.10 | $0.05 | +150.0% | $0.13B | $0.14B | -5.6% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.31 | -$0.12 | +61.3% | $0.13B | $0.13B | -1.8% |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.39 | -$0.30 | +23.1% | $0.11B | $0.10B | +13.4% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$0.27 | -$0.49 | -81.5% | $0.10B | $0.10B | +2.9% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.45 | -$0.30 | +33.3% | $0.09B | $0.10B | -5.3% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$0.74
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$13.43
EPS Est.
-$0.40
EPS Surpr.
-3257.5%
Revenue
$0.16B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$0.11
EPS Est.
$0.02
EPS Surpr.
-650.0%
Revenue
$0.15B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$0.05
EPS Est.
-$0.10
EPS Surpr.
+150.0%
Revenue
$0.13B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.31
EPS Surpr.
+61.3%
Revenue
$0.13B
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.39
EPS Surpr.
+23.1%
Revenue
$0.11B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$0.49
EPS Est.
-$0.27
EPS Surpr.
-81.5%
Revenue
$0.10B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.30
EPS Est.
-$0.45
EPS Surpr.
+33.3%
Revenue
$0.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.05 | $-0.04 | $-0.04 | 1 |
| Q3 FY2027 | $-0.22 | $-0.22 | $-0.21 | 1 |
| Q2 FY2027 | $-0.37 | $-0.36 | $-0.35 | 1 |
| Q1 FY2027 | $-0.44 | $-0.43 | $-0.41 | 1 |
| Q4 FY2026 | $-0.78 | $-0.76 | $-0.74 | 1 |
| Q3 FY2026 | $-1.41 | $-0.67 | $-0.19 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 7 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 4 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 6 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 4 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 7 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -3257.5% | $105.81 | $110.08 | +4.04% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -650.0% | $107.48 | $108.62 | +1.06% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +150.0% | $70.85 | $70.97 | +0.17% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +61.3% | $51.84 | $53.39 | +2.99% |
| ▲ Q2 FY2025 | May 7, 2025 | +23.1% | $41.00 | $41.22 | +0.54% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -81.5% | $49.93 | $50.52 | +1.18% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +33.3% | $41.61 | $42.28 | +1.61% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -8.3% | $39.15 | $38.96 | -0.49% |
Q2 FY2026+4.04%
Report Date
May 6, 2026
EPS Beat/Miss
-3257.5%
Price Before
$105.81
Price After
$110.08
Q1 FY2026+1.06%
Report Date
Feb 25, 2026
EPS Beat/Miss
-650.0%
Price Before
$107.48
Price After
$108.62
Q4 FY2025+0.17%
Report Date
Nov 4, 2025
EPS Beat/Miss
+150.0%
Price Before
$70.85
Price After
$70.97
Q3 FY2025+2.99%
Report Date
Aug 6, 2025
EPS Beat/Miss
+61.3%
Price Before
$51.84
Price After
$53.39
Q2 FY2025+0.54%
Report Date
May 7, 2025
EPS Beat/Miss
+23.1%
Price Before
$41.00
Price After
$41.22
Q1 FY2025+1.18%
Report Date
Feb 26, 2025
EPS Beat/Miss
-81.5%
Price Before
$49.93
Price After
$50.52
Q4 FY2024+1.61%
Report Date
Nov 12, 2024
EPS Beat/Miss
+33.3%
Price Before
$41.61
Price After
$42.28
Q3 FY2024-0.49%
Report Date
Aug 7, 2024
EPS Beat/Miss
-8.3%
Price Before
$39.15
Price After
$38.96
Avg Beat Reaction+1.33%
Avg Miss Reaction+1.45%
Beat Rate4 / 8 quarters
Largest Move+4.04% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MIRM ends December
Mirum Pharmaceuticals, Inc. (MIRM) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-13.43 — missing the analyst consensus of $-0.40 by -3257.5%. The next MIRM earnings date is expected around September 1, 2026.
Each quarter, investors track MIRM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MIRM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MIRM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MIRM earnings · 5 questionsMirum Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. MIRM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MIRM historically reports after market close (AMC).
MIRM earnings datewhen is MIRM earningsMIRM next earnings datewhen does MIRM report earningsMIRM earnings calendar
▸ Source: FMP · Mirum Pharmaceuticals, Inc. SEC filings · US GAAP · Mirum Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026